Recognizing and managing chronic graft-versus-host disease.

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Chronic graft-versus-host disease (GVHD) is a frequent immune-mediated complication following allogeneic hematopoietic cell transplantation (HCT).
• While typically diagnosed within the first year post-HCT, a subset of cases (5-10%) presents beyond the first year.
• Commonly affects skin and mouth, but can involve virtually any organ system, necessitating accurate diagnosis for timely intervention.

Purpose of the Study:

• To review common clinical presentations of chronic GVHD.
• To outline principles for managing chronic GVHD.
• To summarize secondary treatment options and ongoing clinical trials, incorporating new concepts from the 2004 NIH consensus conference.

Main Methods:

• Review of literature focusing on chronic GVHD diagnosis, management, and consensus criteria.
• Discussion of clinical presentations, initial and secondary treatment strategies.
• Summary of frequently used secondary therapies and ongoing clinical trials.

Main Results:

• Consensus criteria for chronic GVHD diagnosis, scoring, pathology, biomarkers, and response criteria were developed following a 2004 NIH conference.
• Corticosteroid-based therapy is the recommended initial treatment for chronic GVHD.
• Optimal secondary treatment remains undefined, with various agents showing potential benefits.

Conclusions:

• Accurate and prompt diagnosis of chronic GVHD is critical to initiate appropriate therapy, minimizing symptoms and preventing irreversible organ damage.
• While initial treatment involves corticosteroids, secondary treatment options are diverse and require further investigation.
• New concepts from the NIH consensus conference provide a framework for understanding and managing chronic GVHD, guiding future research and clinical practice.